Tanios S. Bekaii-Saab, MD, on Next-Generation Sequencing for Gastrointestinal Cancer

Video

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Next-generation sequencing has revolutionized genomic research, helping oncologists to deliver the proper treatment to the proper target, thereby improving outcomes.

Specifically for patients with gastrointestinal cancers, precision therapy has represented a paradigm shift in the way oncologists approach patient care.

In an interview with CancerNetwork®, Tanios S. Bekaii-Saab, MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed why next-generation sequencing is so important for patients with gastrointestinal cancers, as well as the need to make genomic sequencing the standard of care for this entire patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content